Digistain · Oct 2025
Digistain launched its first international laboratory in South Africa with OriGenes and UVU Africa, and the post also highlights the company’s 2025 EIT Health Open Innovation Breast Cancer Challenge win.
Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow
Company research
Public company, workplace, funding, and market signals
Overview
UK medtech/biotech company building an MHRA-cleared, UKCA-marked AI-enabled breast-cancer recurrence-risk platform that analyzes routine FFPE tissue with infrared spectrometry and quantitative histopathology to support treatment decisions and reduce unnecessary chemotherapy.
Primary product
Digistain Test / AI-enabled quantitative histopathology breast-cancer recurrence-risk platform
Founded
2019
Headquarters
Newport Pagnell, Buckinghamshire, United Kingdom
Team size
10-20 employees
Industry
Biotechnology Research
Sub-industry
AI-enabled breast cancer diagnostics / biomarker analytics
Offices
Newport Pagnell, Buckinghamshire, United Kingdom
Open Positions
0 jobs at Digistain
No open positions
Check back later for new openings